What is the prevalence of altered triglycerides in patients with Primary Sclerosing Cholangitis (PSC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prevalence of Altered Triglycerides in Primary Sclerosing Cholangitis

Triglyceride levels are typically normal or only minimally elevated in PSC patients, with only 2-17% having elevated triglycerides depending on disease severity. 1, 2

Lipid Profile Characteristics in PSC

The lipid abnormalities in PSC primarily affect cholesterol rather than triglycerides:

Triglyceride Findings

  • In early-stage PSC patients, only 2% (1 out of 56 patients) had elevated triglyceride levels above normal ranges 2
  • In advanced/pre-transplant PSC patients, 17% demonstrated elevated serum triglyceride levels 2
  • Baseline triglyceride values in a large cohort of 157 PSC patients averaged 102 mg/dL (range 41-698 mg/dL), which falls within normal limits 1

Predominant Lipid Abnormality: Cholesterol

The more clinically relevant lipid disturbance in PSC involves cholesterol:

  • Total cholesterol elevation occurs in 41% of early-stage PSC patients (above 95th percentile) and 29% of pre-transplant patients 2
  • Cholesterol levels correlate with disease severity: Total cholesterol correlates significantly with serum bilirubin levels and liver biochemistries, suggesting cholestasis-driven mechanisms regulate cholesterol metabolism 1, 2
  • Cirrhotic patients have lower total cholesterol levels (186 mg/dL vs. 217 mg/dL in non-cirrhotic, p=0.02) 1

Clinical Implications

Despite elevated cholesterol levels that would typically warrant lipid-lowering therapy, PSC patients paradoxically have no elevated risk for cardiovascular events, with only a 4% incidence of coronary artery disease 1. This is attributed to the presence of lipoprotein-X, an abnormal non-atherogenic LDL particle characteristic of cholestatic liver disease 3.

Key Pitfall to Avoid

Do not aggressively treat hypercholesterolemia in PSC patients with standard cardiovascular risk algorithms, as the cholesterol elevation is mechanistically linked to cholestasis rather than atherosclerotic risk 1. The lipid profile typically normalizes after liver transplantation without specific lipid-lowering interventions 3.

References

Research

Serum lipids in primary sclerosing cholangitis.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.